Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

It will compete with Merck & Co's equally well-established MMR II vaccine in the US, which has had the market mostly to itself since it was approved by the FDA in the 1970s, as well as Merck's ...